

Position Statement: *To be adhered to in line with the [Worcestershire Prescribing Policy](#)*

<p>Treatment</p>	<p>Sativex[®] Oromucosal Spray (Schedule 4 Controlled Drug) as add-on treatment, for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.</p>
<p>Commissioning position</p>	<p>Sativex[®] for multiple sclerosis (MS) is not recommended for people registered with a Worcestershire GP or resident within Worcestershire and not currently registered with any GP: Worcestershire Area Prescribing Committee (APC) did not consider Sativex[®] suitable for use within Worcestershire due to limitations in existing clinical trial data and a lack of evidence of value for money for use of NHS funds. The funding of Sativex[®] will only be considered by Worcestershire Clinical Commissioning Groups (CCGs) in exceptional clinical circumstances through the individual funding request (IFR) process.</p>
<p>Summary of Evidence</p>	<p>In consideration of this position statement the committee considered:</p> <ul style="list-style-type: none"> ➤ NICE clinical guideline 186 conclusion; clinical benefits in improved spasticity, patient satisfaction and ambulation ability were observed with Sativex[®]. However, the evidence was of poor quality and imprecision. ➤ Additionally, one study reviewed by NICE evaluated the cost-effectiveness of Sativex[®] from a UK perspective; an ICER of £49,239 per QALY was calculated. Typically, an ICER of £20,000 per QALY is considered cost-effective. ➤ The long term treatment study contained very small patient numbers. ➤ No head to head studies with other treatments for spasticity have been identified and so there is a lack of evidence suggesting Sativex[®] could be used in place of currently recommended treatments.
<p>Financial implications</p>	<ul style="list-style-type: none"> ➤ The annual cost of Sativex[®] is £6,375 per patient. ➤ Worcestershire CCGs have an estimated population of 585,000 people (Worcestershire Council consensus) and prevalence of MS is approximately 90,500 or 164 per 100,000 (MS Trust). ➤ The prevalence of moderate to severe spasticity is 30% and based on studies 42% of patients progressed to continued treatment. ➤ This gives an estimated annual cost to the Worcestershire CCGs of £771,428.
<p>Other</p>	<p>NICE advise within Clinical Guideline 186: <i>‘Do not offer Sativex[®] to treat spasticity in people with multiple sclerosis because it is not a cost effective treatment.’</i></p>
<p>Approved Date for Review</p>	<p>November 2018 November 2021</p>
<p>References</p>	<ul style="list-style-type: none"> • Department of Health and Social Care (2018) Cannabis-based products for medicinal use. Available at: https://www.gov.uk/government/publications/cannabis-based-products-for-medicinal-use (Accessed: 19 November 2018).

- [Multiple Sclerosis Trust \(2015\) *Prevalence and incidence of multiple sclerosis*. Available at: <https://www.mstrust.org.uk/a-z/prevalence-and-incidence-multiple-sclerosis> \(Accessed: 22 October 2018\).](https://www.mstrust.org.uk/a-z/prevalence-and-incidence-multiple-sclerosis)
- [NICE \(2014\) *Multiple sclerosis: Management of multiple sclerosis in primary and secondary care. Clinical guideline 186. Methods, evidence and recommendations; October 2014*. Available at: <https://www.nice.org.uk/guidance/cg186/evidence/full-guideline-pdf-193254301> \(Accessed: 19 October 2018\).](https://www.nice.org.uk/guidance/cg186/evidence/full-guideline-pdf-193254301)
- [Worcestershire County Council \(2016\) *Population Statistics*. Available at: \[http://www.worcestershire.gov.uk/info/20044/research/795/population_statistics\]\(http://www.worcestershire.gov.uk/info/20044/research/795/population_statistics\) \(Accessed: 22 October 2018\).](http://www.worcestershire.gov.uk/info/20044/research/795/population_statistics)